ProteomeTech Accelerates KOSDAQ Listing... Submits Preliminary Listing Review Application

[Asia Economy Reporter Lee Gwan-joo] ProteomeTech announced on the 7th that it has submitted a preliminary review application to the Korea Exchange for listing on KOSDAQ. The lead underwriter is Kiwoom Securities.

Founded in 2000, ProteomeTech started as a biomarker research and development company discovering disease-specific proteins and has grown since 2010 into a manufacturer of in vitro diagnostic medical devices that measure specific proteins to assess disease conditions.

They sell allergy diagnostic kits (for humans and companion dogs), antibiotic susceptibility diagnostic kits, and immunity monitoring kits. Their main products include the multiplex allergy diagnostic kit 'Protia Allergy-Q 128M', the antibiotic susceptibility diagnostic kit 'Protia AST DL001', and the companion animal allergy diagnostic product 'ANITIA'.

With expansion into overseas markets, they recorded annual sales growth rates of 26% and 21% in 2020 and last year, respectively, and achieved operating profit turnaround last year. Lim Guk-jin, CEO of ProteomeTech, said, “In the past, we aimed to strengthen technological competitiveness, but now it is time to deliver business results through aggressive market entry and enhanced marketing capabilities. We will diligently prepare the remaining procedures to become a global in vitro diagnostic medical device company through the KOSDAQ listing.”